Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists

Shearwood McClelland, III, MD, Kiri A. Sandler, MD, Catherine Degnin, PhD, MS, Yiyi Chen, PhD, Timur Mitin, MD PhD

PII: S1558-7673(17)30337-3
DOI: 10.1016/j.clgc.2017.10.021
Reference: CLGC 964

To appear in: Clinical Genitourinary Cancer

Received Date: 23 October 2017
Accepted Date: 30 October 2017


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Title:

Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists

Authors:

Shearwood McClelland III MD, Kiri A Sandler MD, Catherine Degnin PhD, MS, Yiyi Chen PhD, Timur Mitin MD PhD

Institutions:

1Department of Radiation Medicine, Oregon Health and Science University, Portland, OR; 2Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, CA; 3Biostatistics Shared Resource, Oregon Health and Science University, Portland, OR

Keywords:

Prostate Cancer, Active Surveillance, Radiotherapy, Radical Prostatectomy, Gleason Score, Low Risk, Intermediate Risk

Corresponding Author:

Timur Mitin, M.D., Ph.D.
Department of Radiation Medicine, Oregon Health & Science University
3181 SW Sam Jackson Park Rd, L337
Portland OR, 97239-3098
Phone: 503-494-8756
Fax: 503-346-0237
Email: mitin@ohsu.edu
Abstract

Introduction: The ProtecT trial has provided Level 1 evidence supporting active surveillance for prostate cancer patients with low-risk and intermediate-risk disease. The impact of these findings on the opinions of North American genitourinary (GU) experts regarding the role of active surveillance for these patients has not been previously examined.

Methods: A survey was distributed to 88 practicing North American GU physicians serving on decision-making committees of cooperative group research organizations. Questions pertained to appropriateness of active surveillance in patients with low-risk and intermediate-risk (Gleason 3+4) disease. Opinions regarding active surveillance were correlated with practice patterns using Fisher’s exact test.

Results: 42 radiation oncologists completed the survey. Forty percent have been in practice 20+ years; 90% practice at an academic center. Forty-five percent see 20+ patients/month in consultation. More than 95% recommended active surveillance for Gleason 6 disease, while only 17% recommended active surveillance for Gleason 3+4 disease. There were no demographic differences between supporters or opponents regarding active surveillance with regard to monthly patient volume, practice type, likelihood of self-identifying as an expert brachytherapist, belief in advanced imaging techniques, or preferred default EBRT dose/fractionation for either low-risk or intermediate-risk disease. However, there was a trend towards greater support of active surveillance for Gleason 3+4 disease among experts having practiced <10 years versus 10+ years. (p=0.085).

Conclusions: Active surveillance is almost universally supported by North American GU expert radiation oncologists for low-risk prostate cancer. However, there is very weak support for this strategy in Gleason 3+4 disease despite the ProtecT trial providing Level 1 evidentiary support in both risk groups. There were no significant differences between experts supporting versus opposing active surveillance
for either low-risk or intermediate-risk disease. These preferences may affect the design of future clinical studies, influencing the adoption of active surveillance in North American clinical practice.
Introduction

The ProtecT trial randomized 1,643 men ages 50-69 in the United Kingdom with clinically localized prostate cancer to active surveillance (n = 545), radical prostatectomy (n = 553), or radiotherapy (n = 545) and found that at a median of 10 years, there was no difference in prostate cancer-specific mortality regardless of treatment chosen (1). The results of this trial have provided Level 1 evidence supporting active surveillance for prostate cancer patients, particularly low-risk (Gleason 6) patients, which comprised 77% of the study population (2). Intriguingly, the results also provided evidence supporting active surveillance for intermediate-risk (Gleason 7) disease, which comprised 21% of participants (2). The impact of these findings on the opinions of North American genitourinary (GU) experts regarding the role of active surveillance for low and intermediate-risk prostate cancer patients has not been previously examined.
Methods

Survey Design and Deployment

The survey was designed to identify characteristics of each respondent’s typical practice patterns, as well as to assess their personal opinions on the role active surveillance in low-risk and intermediate-risk prostate cancer patients. Survey questions specified Gleason 3+4 when defining intermediate risk disease. Eighty-eight currently practicing North American GU oncology physicians, who serve on cooperative group research organizations such as NRG Oncology, were contacted by email and invited to complete the survey; their position in cooperative group research organizations served to define them as “experts” for the purposes of this study. The survey was designed and hosted by Research Electronic Data Capture (REDCap), and contained screening questions to ensure respondents were currently practicing, not in training, and specializing in GU oncology (3).

Statistical analysis

Based on responses, participants were categorized as “supporters” or “opponents” of active surveillance for low-risk and intermediate-risk patients. Opinions were correlated with practice patterns using Fisher’s exact test.
Results

Analysis was conducted on 42 radiation oncologist respondents. Seventeen participants (40%) have been in practice for > 20 years and 38 (90%) practice at an academic center. Nineteen participants (45%) see > 20 patients/month in consultation. 95% (40/42) recommended active surveillance for Gleason 6 disease, while only 17% (7/42) recommended active surveillance for Gleason 3+4 disease (Figure 1). There was no significant difference between supporters and opponents of active surveillance for low-risk or Gleason 3+4 disease with regard to years in practice (+-10 years, +- 20 years), monthly patient volume, practice type, belief in advanced imaging techniques, likelihood of self-identifying as an expert brachytherapist, or treatment preferences for EBRT dose/fractionation for Gleason 3+4 disease. However, there was a trend towards greater support of active surveillance for Gleason 3+4 disease among experts who practiced fewer than 10 years since residency program completion, in comparison to experts with greater than 10 years of professional experience. (p=0.085).
Discussion

Committees of cooperative group research organizations play an integral role in the design of clinical studies and consequently the degree of acceptance or rejection of treatment modalities (4). These experts also take part in decision-making committees of organization that issue national treatment guidelines, often are faculty members teaching the next generation of clinicians and render expert opinions for patients seeking care at large academic institutions. Their opinions shape the current and future national guidelines and recommendations and the design of clinical trials. The ProtecT trial has had a major impact on the GU oncologic community; for some it has resulted in dramatic changes in the standard of care, while others have resisted its implications of active surveillance being comparable to radical prostatectomy or radiotherapy for low-risk and intermediate-risk prostate cancer (5-6). Given the impact of cooperative research group organizations on shaping the future direction of care, we sought to determine the acceptance of active surveillance among North American GU experts in light of the ProtecT results.

Our findings indicate that while active surveillance has been widely adopted for low-risk prostate cancer (95%), it has largely failed to achieve adoption for Gleason 3+4 disease, with more than 80% of participants in our study opposed to active surveillance for this group of patients. The findings that there were no significant demographic differences between supports and opponents of active surveillance recommendation for low-risk and Gleason 3+4 disease serve as a window into the direction of active surveillance in both present and future North American clinical trials. Although it did not reach statistical significance, it is noteworthy to mention that opposition to active surveillance for Gleason 3+4 disease approached significance for experts having practiced at least 10 years versus less than 10 years; this may indicate that radiation oncologists having finished residency more recently may be more
comfortable with advising active surveillance for Gleason 3+4 disease, which is consistent with the more recent evidence supporting active surveillance for low-risk disease.

Limitations of this study include its small sample size, given that the target population was GU physicians who served on cooperative group research organizations. Furthermore, because responses were in the format of multiple choice, the full range of opinions may not have been adequately captured. Additionally, survey fatigue can result in responses that are not genuine; we sought to curb this by not offering an incentive (financial or otherwise) to complete the survey that we hope maximized the rate of legitimate responses. Another limitation is that this survey did not assess whether responders saw patients for the first time together with the surgeon (in multidisciplinary clinic), or only after being referred by the urologist; this is important since the multidisciplinary clinic approach is associated with increased selection of active surveillance, adherence to National Comprehensive Cancer Network guidelines, and minimization of overtreatment in in low-risk prostate cancer patients (7). Finally, an important consideration is the underrepresentation of minorities in these patient populations with regard to clinical trials; a recent publication warned that the failure of the ProtecT trial to stratify results by patient race may put its overall recommendation of active surveillance for low-risk prostate cancer on thinner ice for African-American than Caucasian men, particularly since less than 1% of ProtecT participants were of African descent, a number far smaller than the true proportion of African-Americans in the United States (US) which was 13% in the most recent US Census (2, 8-9). Support for active surveillance in African-Americans, particularly for intermediate-risk but also for low-risk disease, is on even thinner ice since African-Americans may harbor more aggressive disease than Caucasians (10). This study limitation may be due to the lack of granularity in the survey questions regarding the racial demographics of patients being treated, and is an important area for future studies to address.
In conclusion, active surveillance is well-supported by North American GU expert radiation oncologists for low-risk but not intermediate-risk prostate cancer, despite the results of the ProtecT trial providing Level 1 evidentiary support for active surveillance in both risk groups. There were no significant differences between experts supporting versus opposing active surveillance for either low-risk or intermediate-risk disease. These preferences may affect the design of future clinical studies, influencing the adoption of active surveillance in North American clinical practice.
References


Figure 1: Depiction of survey results from 42 North American genitourinary oncology expert radiation oncologists. (AS = Active surveillance; PCa = Prostate cancer)